Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Death

Carcinoma

Carcinoma, Squamous Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Hypopharyngeal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Antibodies

Antibodies, Monoclonal

Capecitabine

Cisplatin

Immunomodulating Agents

Immunoglobulins

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Induction chemotherapy combined with immunotherapy (TPF + Camrelizumab), q3w, 3 cycles in total:

Docetaxel (domestic) 75 mg/m2 i.v. d1, Cisplatin 25 mg/m2 i.v. d1-3, Capecitabine 800 mg/m2 po bid d1-d14, Camrelizumab 200mg i.v. d1;

Radical radiotherapy plus concurrent immunotherapy (CR or PR):

Radiotherapy: Using intensity-modulated radiation therapy (IMRT). Primary site: GTV dose 66 (2.2Gy / fraction)-70 Gy (2Gy / fraction)；CTV 1.6-1.9 Gy / fraction. Cervical lymph nodes: Radiotherapy plan is the same as the radiotherapy plan of original site; Concurrent immunotherapy : Camrelizumab 200mg i.v. d1, d22;

Maintenance period:

After completing concurrent chemoradiotherapy combined with immunotherapy, Camrelizumab 200 mg q3w will be given up to 12 months (calculated from the time of the first dose of PD-1 immunotherapy).

Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Camrelizumab

Liang Zhou, PhD.

This is a single-center, multidisciplinary, open-label, single-arm prospective clinical study.

In this study, 51 patients with hypohparyngeal carcinoma will be enrolled, These patients who have locally advanced-stage disease, including TNM stage cT3-4aN0-2M0 (AJCC 7th) and require a total laryngectomy as an initial therapy. Patients who achieved a CR or PR at the primary site after three cycles of TPF-regimen chemotherapy combined with immuotherapy will be referred for definitive RT and immuotherapy, while patients who received an evaluation of PD or SD at the primary site were referred for surgery followed by adjuvant RT/CRT.

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

The proportion of patients with partial and complete response as defined by RECIST 1.1 after induction therapy

Eye & ENT Hospital of Fudan University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma	NCT04156698	Hypopharyngeal ... Immunotherapy Chemotherapy	Docetaxel Cisplatin Capecitabine Camrelizumab	18 Years - 70 Years	Eye & ENT Hospital of Fudan University
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma	NCT04156698	Hypopharyngeal ... Immunotherapy Chemotherapy	Docetaxel Cisplatin Capecitabine Camrelizumab	18 Years - 70 Years	Eye & ENT Hospital of Fudan University

Spots Global Cancer Trial Database for safety profiles